Strain differences in the metabolic activation of aflatoxin B₁ in the rat

References

• Al-Dabbagh S. G., Idle J. R., Smith R. L. Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains. Journal of Pharmacy and Pharmacology 1981; 33: 161–164
   PubMed Web of Science ®Google Scholar
• Alpert M. E., Hurr M. S. R., Wogan G. N., Davidson C. S. Association between aflatoxin content of food and hepatoma frequency in Uganda. Cancer 1971; 28: 253–260
   PubMed Web of Science ®Google Scholar
• Ames B. N., McCann J., Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutation Research 1975; 31: 347–364
   PubMed Web of Science ®Google Scholar
• Beland F. A., Dooley K. L., Casciano D. A. Rapid isolation of carcinogen-bound DNA and RNA by hydroxylapatite chromatography. Journal of Chromatography 1979; 174: 177–186
   PubMed Web of Science ®Google Scholar
• Croy R. G., Wogan G. N. Quantitative comparison of covalent aflatoxin-DNA adducts formed in rat and mouse livers and kidneys. Journal of the National Cancer Institute 1981; 66: 761–768
   PubMed Web of Science ®Google Scholar
• Distlerath L. M., Reilly P. E. B., Martin M. V., Davis G. G., Wilkinson G. R., Guengerich F. P. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 1985; 260: 9057–9067
   PubMed Web of Science ®Google Scholar
• Garner R. C., Miller E C., Miller J. A. Liver microsomal metabolism of aflatoxin B1 to a reactive derivative toxic to Salmonella typhimurium TA1530. Cancer Research 1972; 32: 2058–2066
   PubMed Web of Science ®Google Scholar
• Hsieh D. P. H., Wong J. J. Metabolism and toxicity of aflatoxins. Biological Reactive Intermediates-II. Chemical Mechanisms and Biological Effects, Part B, R. Snyder, D. V. Parke, J. J. Kocsis, D. J. Jollow, C. G. Gibson, C. M. Witmer. Plenum Press, London 1982; 847–863
   Google Scholar
• Idle J. R., Mahgoub A., Sloan T. P., Smith R. L., Mbanefo C. O., Bababunmi E. A. Some observations of the oxidative phenotype status of Nigerian patients presenting with cancer. Cancer Letters 1981; 11: 331–337
   PubMed Web of Science ®Google Scholar
• Kahn G. C., Rubenfield M., Davies D. S., Murray S., Boobis A. R. Sex and strain differences in hepatic debrisoquine 4-hydroxylase activity of the rat. Drug Metabolism and Disposition 1985; 13: 510–516
   PubMedGoogle Scholar
• Kupfer A., Desmond P., Patwardhan R., Schenker S., Branch R. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clinical Pharmacology and Therapeutics 1984; 35: 33–39
   PubMed Web of Science ®Google Scholar
• Linsell C. A., Peers F. G. Field studies on liver cell cancer. Origins of Human Cancer, H. A. Hyatt, J. D. Watson, J. A. Winsten. Cold Spring Harbour Laboratory, Cold Spring Harbour 1977; 549–556
   Google Scholar
• Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; ii: 584–586
   Web of Science ®Google Scholar
• McCann J., Choi E., Yamasaki E., Ames B. N. Detection of carcinogens as mutagens in the Salmonella/microsome test. Assay of 300 chemicals. Proceedings of the National Academy of Sciences of the United States of America 1975; 72: 5135–5139
   PubMed Web of Science ®Google Scholar
• Newberne P. M., Butler W. H. Acute and chronic effects of aflatoxin on the liver of domestic and laboratory animals. A Review. Cancer Research 1969; 29: 236–250
   PubMed Web of Science ®Google Scholar
• O'Brien K., Moss E., Judah D., Neil G. Metabolic basis of the species difference to aflatoxin B1 induced hepatotoxicity. Biochemical and Biophysical Research Communications 1983; 114: 813–821
   PubMed Web of Science ®Google Scholar
• Oesch F., Guenthner T. M. Effects of the modulation of epoxide hydrolase activity on the binding of benzo[a]pyrene metabolites to DNA in the intact nuclei. Carcinogenesis 1983; 4: 57–65
   PubMed Web of Science ®Google Scholar
• Oesch F., Zimmer A., Glatt H. R. Microsomal epoxide hydrolase in different rat strains. Biochemical Pharmacology 1983; 32: 1783–1788
   PubMed Web of Science ®Google Scholar
• Pelkonen O., Boobis A. R., Yagi H., Jerina D. M., Nebert D. W. Tentative identification of benzo[a]pyrene metabolite-nucleoside complexes produced in vitro by mouse liver microsomes. Molecular Pharmacology 1978; 14: 306–322
   PubMed Web of Science ®Google Scholar
• Plummer S., Boobis A. R., Davies D. S. Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man. Archives of Toxicology 1986; 58: 165–170
   PubMedGoogle Scholar
• Schneider W. C. Determination of nucleic acids in tissues by pentose analysis. Methods in Enzymology 1957; 3: 680–691
   Web of Science ®Google Scholar
• Scott J., Poffenbarger P. L. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 1979; 28: 41–51
   PubMed Web of Science ®Google Scholar
• Sloan T. P., Mahgoub A., Lancaster R., Idle J. R., Smith R. L. Polymorphism of carbon oxidation of drugs and clinical implications. British Medical Journal 1978; 2: 655–657
   PubMed Web of Science ®Google Scholar
• Swenson P. H., Lin J. K., Miller E. C., Miller J. A. Aflatoxin B1-2,3-oxide as a probable intermediate in the covalent binding of aflatoxins B1 and B2 to rat liver DNA and ribosomal RNA, in vivo. Cancer Research 1977; 37: 172–181
   PubMed Web of Science ®Google Scholar
• Tee L. B. G., Seddon T., Boobis A. R., Davies D. S. Drug metabolising activity of freshly isolated human hepatocytes. British Journal of Clinical Pharmacology 1985; 19: 279–294
   PubMed Web of Science ®Google Scholar
• Waring R. H., Mitchell S. C., Idle J. R., Smith R. L. Genetically determined impaired drug oxidation. Lancet 1981; i: 778
   Google Scholar